[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"heart-neoplasms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:heart-neoplasms":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":20,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100579916","the-safety-and-efficacy-evaluation-of-echocardiography-guided-percutaneous-radiofrequency-ablation-for-cardiac-tumors-a-single-arm-prospective-single-center-clinical-study-100579916",false,"NCT06830512","The Safety and Efficacy Evaluation of Echocardiography-guided Percutaneous Radiofrequency Ablation for Cardiac Tumors: a Single-arm, Prospective, Single-center Clinical Study","Inclusion Criteria:\n\n1. Hemodynamic changes caused by cardiac tumors or patients with obvious clinical symptoms such as chest tightness, shortness of breath, palpitations, etc., or the risk of embolization of intracardial tumors;\n2. Patients who cannot be completely excised by surgery, cannot tolerate surgery or refuse surgery;\n3. The patient was informed of the nature of the clinical study and agreed to participate in all the requirements of the clinical study, signed the informed consent, and agreed to complete the follow-up and follow-up examination required.\n\nExclusion Criteria:\n\n1. Previously documented persistent ventricular tachycardia or ventricular fibrillation, supraventricular tachycardia with hemodynamic disturbance, cardiac arrest, and high atrioventricular block;\n2. Previous history of tumor or thromboembolism exfoliating organ embolism;\n3. Combined with other heart diseases requiring surgical treatment;\n4. Active infections should be treated with antibiotics;\n5. Bleeding constitution and coagulation disorders, or anticoagulation, antiplatelet therapy contraindications;\n6. Patients who are pregnant, breastfeeding or planning to become pregnant during the clinical study;\n7. The disease will cause difficulties in the evaluation of treatment, such as mental illness, metabolic disease, etc.;\n8. Patients who cannot tolerate general anesthesia;\n9. Severe liver, kidney, lung, brain and other major organ failure;\n10. There are no patients who are suitable for the injection path of Liwen operation;\n11. Other diseases deemed unsuitable for inclusion by the researchers;\n12. The researcher judged that the patients' dependence was poor and could not complete the study.","ALL",{"count":17,"type":18},40,"ESTIMATED","INTERVENTIONAL",[21],"NA","The safety and efficacy evaluation of echocardiography-guided percutaneous radiofrequency ablation (Liwen prcocedure) for cardiac tumors: a single-arm, prospective, single-center clinical study.",[24],"Heart Neoplasms",[26],"cardiac tumors；echocardiography-guided percutaneous radiofrequency ablation; safety; efficacy","RECRUITING","2025-02-13",{"date":30,"type":31},"2025-02-17","ACTUAL",{"date":33,"type":31},"2024-01-24",{"date":35,"type":18},"2026-12-30",{"name":37,"class":38},"Xijing Hospital","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":66,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":39},"100516173","prognosis-prediction-system-of-patients-with-cardiovascular-and-cerebrovascular-diseases-based-on-multi-omics-100516173","NCT06001073","Prognosis Prediction System of Patients With Cardiovascular and Cerebrovascular Diseases Based on Multi-omics","Prognosis Prediction System of Patients With Cardiovascular and Cerebrovascular Diseases Based on Multi-omics (PROSPECT): a National, Multicenter, Retrospective-prospective, Cohort Study","PROSPECT","Inclusion Criteria:\n\n* Patients who are regularly visited and followed up in the appropriate patient; department.\n* All patients met at least one of the following diagnostic criteria for cardiovascular and cerebrovascular diseases:\n* coronary artery disease group;\n* arrhythmia group;\n* heart valve disease group;\n* aortic dissection group;\n* cardiac masses group;\n* myocarditis group;\n* hypertension group;\n* cardiomyopathy group;\n* structural heart disease group;\n* ischemic cerebrovascular disease group;\n* hemorrhagic cerebrovascular disease group;\n* intracranial space occupying lesion group.\n\nExclusion Criteria:\n\n* Age \\\u003C3 years or \\>80 years old;\n* Pregnant and lactating women;\n* The patient declined to provide informed consent to participate in the study;\n* None of the above was met, but the patient was temporarily unable to sign the informed consent form due to coma and other reasons, and no legal representative signed it instead. Depending on the patient's condition, the patient may not be able to regain consciousness and sign the informed consent form.","3 Years","80 Years",{"count":51,"type":18},25000,"OBSERVATIONAL","The etiology and specific pathogenesis of many cardiovascular diseases such as coronary atherosclerosis, cardiomyopathy, atrial fibrillation, and stroke are still unclear. Improving diagnosis and treatment, clarifying the pathogenesis, and providing scientific basis for the prevention and treatment are hot research topics in the study of cardiovascular and cerebrovascular diseases. This study intends to collect clinical data and biological specimen data of patients with cardiovascular and cerebrovascular diseases who meet the inclusion and exclusion criteria, and use multi-omics technology to deeply understand the pathogenic mechanisms of cardiovascular and cerebrovascular diseases and provide new ideas for specific and individualized treatment of patients with cardiovascular and cerebrovascular diseases, to construct early predictive prognostic models and provide a basis for effective treatment of clinical practice in patients with cardiovascular and cerebrovascular diseases.",[55,56,57,58,24,59,60,61,62,63,64,65],"Coronary Artery Disease","Arrhythmias, Cardiac","Heart Valve Diseases","Aortic Dissection","Myocarditis","Hypertension","Cardiomyopathies","Structural Heart Disease","Ischemic Cerebrovascular Disease","Hemorrhagic Cerebrovascular Disease","Brain Neoplasms",[67,68,69,70],"Cardiovascular diseases","Cerebrovascular diseases","Prognosis","Multi-omics","2024-07-10",{"date":73,"type":31},"2024-07-12",{"date":75,"type":31},"2022-12-05",{"date":77,"type":18},"2028-12-31",{"name":79,"class":38},"First Affiliated Hospital Xi'an Jiaotong University"]